Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.
40 Stocks Moving In Friday’s Mid-Day Session
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.
Wedbush Downgrades Turning Point to Neutral, Raises Price Target to $76
Wedbush analyst David Nierengarten downgrades Turning Point (NASDAQ:TPTX) from Outperform to Neutral and raises the price target from $61 to $76.
Bristol Myers Squibb to Acquire Turning Point Therapeutics For $76/Share
Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to
B of A Securities Initiates Coverage On Turning Point with Buy Rating, Announces Price Target of $58
B of A Securities analyst Alec Stranahan initiates coverage on Turning Point (NASDAQ:TPTX) with a Buy rating and announces Price Target of $58.
SVB Leerink Maintains Outperform on Turning Point, Lowers Price Target to $101
SVB Leerink analyst Andrew Berens maintains Turning Point (NASDAQ:TPTX) with a Outperform and lowers the price target from $107 to $101.
Turning Point Therapeutics Reports Was Granted Breakthrough Therapy Designation For Its Repotrectinib Treatments In Patients With 1 Prior Tyrosine Kinase Inhibitor, No Prior Chemo
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration
Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate
Turning Point Therapeutics Inc (NASDAQ:TPTX) entered into an exclusive license agreement with LaNova Medicines Limited to develop and commercialize LM-302, in the U.S.…